[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619-949-3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 57, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 67, "title": "President & Director", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}, {"maxAge": 1, "name": "Ms. Seline E. Miller CPA", "age": 53, "title": "Senior Vice President of Finance", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.75, "open": 12.54, "dayLow": 12.04, "dayHigh": 12.54, "regularMarketPreviousClose": 12.75, "regularMarketOpen": 12.54, "regularMarketDayLow": 12.04, "regularMarketDayHigh": 12.54, "forwardPE": 26.304348, "volume": 43254, "regularMarketVolume": 43254, "averageVolume": 112006, "averageVolume10days": 58860, "averageDailyVolume10Day": 58860, "bid": 8.98, "ask": 15.61, "bidSize": 200, "askSize": 200, "marketCap": 1038449920, "fiftyTwoWeekLow": 8.26, "fiftyTwoWeekHigh": 26.37, "priceToSalesTrailing12Months": 9.3061905, "fiftyDayAverage": 11.1876, "twoHundredDayAverage": 12.63225, "currency": "USD", "enterpriseValue": 1249466240, "profitMargins": -0.77042997, "floatShares": 15817936, "sharesOutstanding": 85822304, "sharesShort": 376581, "sharesShortPriorMonth": 457298, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.74704003, "heldPercentInstitutions": 0.01502, "shortRatio": 11.66, "shortPercentOfFloat": 0.026300002, "impliedSharesOutstanding": 90432600, "bookValue": -0.207, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.904, "netIncomeToCommon": -85970000, "trailingEps": -1.04, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 11.197, "enterpriseToEbitda": 62.221, "52WeekChange": 0.060473323, "SandP52WeekChange": 0.19995654, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GYRE", "underlyingSymbol": "GYRE", "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "firstTradeDateEpochUtc": 1144848600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fcf12068-c88b-34d0-8632-7e45e01ea8d2", "messageBoardId": "finmb_100542295", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.1, "recommendationKey": "none", "totalCash": 25100000, "totalCashPerShare": 0.293, "ebitda": 20081000, "totalDebt": 1956000, "quickRatio": 2.871, "currentRatio": 3.436, "totalRevenue": 111587000, "debtToEquity": 2.095, "revenuePerShare": 1.464, "returnOnAssets": 0.10181, "returnOnEquity": -0.82741, "grossProfits": 107404000, "freeCashflow": 8442836, "operatingCashflow": 8333000, "earningsGrowth": -0.705, "revenueGrowth": -0.14, "grossMargins": 0.96251, "ebitdaMargins": 0.17996, "operatingMargins": 0.12932, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]